Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release
  1. September 09, 2026

    Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

    Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with M...

    View more
  2. September 08, 2026

    HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

    The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The...

    View more
  3. September 07, 2026

    Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — September 6, 2026   Today, shares of Harbour BioMed (the "Company"; HKEX: 02142.HK) wer...

    View more
  4. August 27, 2026

    Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — August 27, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutic...

    View more
  5. August 27, 2026

    Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — August 27, 2026   Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), ...

    View more
  6. August 18, 2026

    Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — August 18, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutic...

    View more
  7. August 06, 2026

    Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — August 6, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to th...

    View more
  8. July 27, 2026

    Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — July 27, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the...

    View more
  9. July 23, 2026

    Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – July 23, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...

    View more
  10. July 15, 2026

    Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — July 15, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG